Capsule endoscopy market seen reaching $2.17 billion by 2035

The global capsule endoscopy market is projected to grow from $0.78 billion in 2026 to $2.17 billion by 2035, driven by rising gastrointestinal disease prevalence, faster AI-assisted image reading and broader reimbursement. North America leads now, while Asia-Pacific is expected to post the fastest growth through 2035.

Why it matters: - The capsule endoscopy market is moving from a niche diagnostic tool to a mainstream option for gastrointestinal screening and follow-up. - Growth is tied to higher demand for non-invasive GI testing, earlier cancer detection and faster clinical workflows. - Reimbursement gains and AI-assisted reading are lowering barriers for hospitals and outpatient centers.

What happened: - Market Research Future projects the global capsule endoscopy market will rise from $0.78 billion in 2026 to $2.17 billion by 2035. - The forecast implies a 12.0% compound annual growth rate for 2026-2035. - The market base was estimated at $0.70 billion in 2025. - The report links growth to rising gastrointestinal disorder prevalence, AI-powered automated image reading and reimbursement expansion. - A free sample is available at Request A Free Sample.

The details: - Colorectal cancer burden is expected to keep rising as lifestyle patterns change and populations age. - Wireless capsule endoscopy is positioned as a non-invasive option for small-bowel evaluation when traditional methods are harder to use. - National cancer registries in India and Brazil are reporting higher detection rates as screening programs mature. - AI-assisted capsule reading is replacing manual review in more workflows. - Medtronic's RAPID software helped establish AI-assisted capsule reading as a viable model. - The US FDA increased 510(k) clearances for AI-assisted capsule reading software in 2024. - Average image review time fell from 90 minutes to less than 25 minutes. - CMS reimbursement expansion under the hospital outpatient prospective payment system and physician fee schedule supports provider adoption. - NHS England data show colon capsule endoscopy rollout across 40+ trusts reduced colonoscopy backlogs and saved about $800-$1,200 per patient in facility costs. - Market Research Future's report is available at Read Detailed Insights.

Between the lines: - The market is being pulled by policy, technology and procurement at the same time, which makes the growth story more durable than a simple device-cycle upgrade. - Hospitals are moving toward workflow efficiency, not just hardware specs, as software and cloud-connected reading systems become more important. - Asia-Pacific is becoming a major growth engine because of reimbursement support, local manufacturing and rising cancer screening demand. - China has the largest regional share in Asia-Pacific, helped by domestic devices priced 35%-40% below imported alternatives. - The US remains the largest national market because payer coverage, CMS claims growth and AI adoption reinforce each other. - The top five companies account for about 65%-72% of revenue, so the market remains concentrated even as lower-cost competitors expand.

What's next: - The report expects AI-integrated capsule diagnostics and cloud-based reading platforms to keep expanding through 2035. - By 2030, about 40% of newly diagnosed obscure GI bleeding cases are expected to use AI-assisted capsule reading followed by matched therapeutic intervention, according to the forecast. - Future product growth is likely to favor recorders, workstations and software platforms over capsule hardware alone. - More information on related research is available through the report's linked resources, including endoscopy devices, gastrointestinal drugs and medical imaging.

The bottom line: - Capsule endoscopy is shifting from a specialized GI test to a reimbursed, AI-enabled diagnostic platform with room for sustained global growth.